Protein Sciences Announces Completion of Targeted Enrollment of Subjects in a Phase II/III Clinical Trial of FluBlok(TM), its Patented Cell Culture Influenza Vaccine

Nov 22, 2004, 00:00 ET from Protein Sciences Corporation

    MERIDEN, Conn., Nov. 22 /PRNewswire/ -- Protein Sciences Corporation, a
 world leader in developing the next generation of safer, more effective human
 and veterinary vaccines, announced today that it completed enrollment of 460
 subjects in a Phase II/III proof of principle/field study of FluBlok(TM), its
 patented cell culture influenza vaccine.  The study is comparing two different
 doses of FluBlok to a placebo group.  The study sites are the University of
 Rochester, NY (Dr. John Treanor, Study Principal Investigator), the University
 of Cincinnati Children's Hospital (Dr. Gilbert Schiff) and the University of
 Virginia (Dr. Frederick Hayden).
     Daniel D. Adams, President and CEO of Protein Sciences stated, "We believe
 that as enrolled the trial we will not only achieve our primary endpoint --
 showing safety and establishing a commercial dose for FluBlok -- but also will
 show by statistically significant data that FluBlok protects against influenza
 under field conditions as well or better than licensed vaccines."
     About Protein Sciences.  Founded in 1983, Protein Sciences is a vaccine
 company focused primarily on using modern technology to make the next
 generation of safer and more effective human and animal vaccines.  The Company
 has a pipeline of patented products that includes two influenza vaccines that
 have completed Phase II(b) human clinical trials, one of which, FluBlok, is in
 Phase II/III trials, and a SARS vaccine and erythropoietin that have completed
 animal tests and will enter human testing soon.  All products are recombinant
 proteins that are made using the Company's patented protein expression
 technology, the baculovirus protein expression system (BEVS), in which it is
 the world leader.  Protein Sciences also has a service business that is driven
 by its BEVS technology including GeneXpress(R) (developing and manufacturing
 vaccines, therapeutics and diagnostics for customers) and manufacturing and
 selling proteins related to HIV/AIDS, SARS, influenza and pandemic influenza
 for research use.  The Company has developed all of its products and
 businesses internally and retains commercial rights to its major products. Its
 facilities are located in Meriden, CT and include offices, research and
 development laboratories and a cGMP pilot plant capable of manufacturing
 clinical materials at the 600-Liter scale.  Website:

SOURCE Protein Sciences Corporation